Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies

NCT02013128 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT02013128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 6, 2014
Completion date
December 31, 2015
Enrollment
66 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, mantle cell lymphoma